Alpha Tau Medical Ltd (DRTS) has released an update.
Alpha Tau Medical Ltd. reports promising clinical outcomes, with a near 100% response rate in treated cancer lesions and a 2-year local recurrence-free survival rate of 77%, alongside a solid financial standing including $74.1 million in funds to cover operations for the next two years. The company’s Alpha DaRT therapy, targeting hard-to-treat cancers, has seen strong interest and demand for clinical trials, especially in the ongoing internal organ trials. Alpha Tau also anticipates significant data releases and regulatory advancements for its innovative cancer treatments by the end of 2024 and into 2025.
For further insights into DRTS stock, check out TipRanks’ Stock Analysis page.
